Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression / Festi, D., Lodato, F., Mazzella, G., Colecchia, A. - In: Hepatitis C Virus Disease. Immunobiology and Clinical ApplicationsUSA : Springer, 2008. - ISBN 9780387713755. - pp. 215-236 [10.1007/978-0-387-71376-2_11]
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression
COLECCHIA, ANTONIO
2008
Abstract
Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
